TNEA therapy promotes the autophagic degradation of NLRP3 inflammasome in a transgenic mouse model of Alzheimer’s disease via TFEB/TFE3 activation. This evidence concerns the gene TFEB and early-onset autosomal dominant Alzheimer disease.